Rezurock (belumosudil) — United Healthcare
chronic graft-versus-host disease (chronic GVHD)
Initial criteria
- Diagnosis of chronic graft-versus-host disease (chronic GVHD)
- History of failure of at least two prior lines of systemic therapy [e.g., corticosteroids, mycophenolate, tacrolimus, etc.]
Reauthorization criteria
- Documentation of positive clinical response to Rezurock therapy
Approval duration
12 months